Table 2.
Study (year) | Treatment(s) | Treatment line |
Reference |
---|---|---|---|
Swain et al. (2013) | Pertuzumab + trastuzumab + docetaxel |
First | 9 |
Swain et al. (2013) | Trastuzumab + docetaxel | First | 9 |
Verma et al. (2012) | T-DM1 | Second | 10 |
Blackwell et al. (2010) | Trastuzumab + lapatinib | Second | 13 |
Geyer et al. (2006) | Capecitabine + lapatinib | Third | 12 |
von Minckwitz et al. (2009) |
Trastuzumab + capecitabine | Third | 11 |
Blackwell et al. (2010) | Trastuzumab + lapatinib | Third | 13 |
T-DM1: trastuzumab emtansine.